ARA 290 — Safety, Research, Risks & Legal Status

Not medical advice. ARA 290 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	erythropoietin derivative, EPO agonist
Category	Peptide
EPO	Erythropoietin; hormone produced mainly by kidneys; stimulates red blood cell production and has tissue-protective roles
JAK2	Janus kinase 2; protein tyrosine kinase activated by EPO binding
WADA	World Anti-Doping Agency; maintains banned substances list for sports
US legal status	Research chemical; EPO and its analogs are banned in sport (WADA); not FDA-approved for general human use; prescription EPO exists for anemia

What is ARA 290?

Synthetic peptide that activates erythropoietin (EPO) signaling; studied for tissue repair, neuroprotection, and organ damage mitigation. ARA-290 is designed to activate EPO's tissue-protective effects while minimizing erythropoiesis (red blood cell production), distinguishing it from classical EPO.

How it works

ARA-290 binds the EPO receptor on tissues and activates JAK2-STAT5 signaling, promoting anti-apoptotic and cytoprotective pathways. Unlike classical EPO, ARA-290 is engineered to minimize erythropoietin-dependent erythropoiesis while preserving neuroprotection, reducing thrombosis risk theoretically, though human data on this selectivity is incomplete.

Background & history

ARA-290 was developed in the early 2000s by Araim Pharmaceuticals as a selective EPO receptor agonist. Clinical development focused on diabetic neuropathy and acute kidney injury. The molecule was designed to overcome EPO's thrombotic and hypertensive side effects while retaining tissue protection, but clinical translation has been limited.

What the research says

Preclinical and early-stage human trials mainly in neuropathy; some data in acute kidney injury; very limited long-term safety records in humans. Phase 2 data in diabetic peripheral neuropathy shows pain reduction, but efficacy lacks large randomized controlled trials; tissue-protective mechanisms are plausible but not fully confirmed in human pathology.

Reported effects

Studied to reduce neuropathic pain in diabetic patients
Reported to activate tissue-protective (not just erythropoietic) EPO pathways
Animal models suggest organ-protective effects after injury
May promote vascular repair mechanisms
Preclinical data suggest neuroprotection in ischemic conditions

Dosing & administration (informational)

Human trials have ranged 0.3-2.0 mg (subcutaneous or intravenous), typically dosed multiple times per week over 12-16 week protocols. Preclinical animal studies used doses scaled to body weight. No standard human dosing established; overdose and long-term accumulation effects are unknown.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

EPO agonists carry risk of blood clotting (thrombosis) and hypertension; no long-term human safety data
Banned by WADA for sports performance; not intended for athletic enhancement
Synth must be sterile, endotoxin-free, GMP: contaminated peptide can trigger immune reactions
Injection-only route; proper aseptic technique and cold chain required
Contraindicated in polycythemia, uncontrolled hypertension, active thrombosis; avoid in pregnancy
Hematocrit elevation possible; periodic monitoring recommended if used

Drug & supplement interactions

Potential interaction with anticoagulants and antiplatelet drugs (increased thrombosis risk unclear)
Blood pressure medications may require adjustment if hypertension occurs
Iron supplementation: EPO agonists increase RBC production, requiring adequate iron
Erythropoiesis-stimulating agents (ESAs) should not be combined (redundant effect)

Who should avoid it

Active thrombotic disease or history of stroke (thrombosis risk)
Polycythemia vera or uncontrolled high hematocrit
Uncontrolled hypertension (blood pressure elevation possible)
Pregnancy (insufficient data; potential fetal risk)
WADA-restricted sports or competitions (banned substance)

How it is commonly combined

Not recommended to combine with other EPO agonists, G-CSF, or erythropoiesis-stimulating agents. Off-label stacking with general neuroprotective compounds (alpha-lipoic acid, benfotiamine) has been attempted informally, but no safety or efficacy data exist.

Legal & regulatory. Research chemical; EPO and its analogs are banned in sport (WADA); not FDA-approved for general human use; prescription EPO exists for anemia

Quality & harm reduction

S
t
r
i
c
t
r
e
q
u
i
r
e
m
e
n
t
:
t
h
i
r
d
-
p
a
r
t
y
C
O
A
f
r
o
m
c
e
r
t
i
f
i
e
d
l
a
b
.
H
P
L
C
-
M
S
p
u
r
i
t
y
9
8
%
+
;
L
C
-
M
S
m
a
s
s
c
o
n
f
i
r
m
a
t
i
o
n
.
E
n
d
o
t
o
x
i
n
t
e
s
t
i
n
g
:
u
s
e
E
U
P
h
a
r
m
a
c
o
p
o
e
i
a
o
r
L
A
L
(
l
i
m
i
t
l
e
s
s
t
h
a
n
0
.
2
5
I
U
/
k
g
b
o
d
y
w
e
i
g
h
t
e
q
u
i
v
a
l
e
n
t
)
.
S
t
e
r
i
l
e
,
s
i
n
g
l
e
-
u
s
e
v
i
a
l
s
;
r
e
f
r
i
g
e
r
a
t
i
o
n
(
2
-
8
°
C
)
o
r
s
t
a
b
l
e
f
r
o
z
e
n
(
-
2
0
°
C
)
;
n
e
v
e
r
r
e
u
s
e
o
p
e
n
e
d
v
i
a
l
.

Safer, legal alternative we recommend

Vigorous aerobic exercise and iron-rich whole foods. Natural EPO production increases with hypoxic training; combined with good nutrition, supports endurance and tissue repair without injection or thrombosis risk.

See our recommended pick

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Can I use ARA-290 to boost athletic performance?

No. EPO agonists are banned in sport (WADA list) and illegal for performance enhancement; using them is doping.

What are the risks?

Blood clots, stroke, heart attack, hypertension. Long-term human data is lacking; these are serious risks taken in research studies only.

Is ARA-290 safer than EPO?

Possibly more selective for tissue protection than pure EPO, but human data is minimal. Do not assume it is safe.

How is it dosed in studies?

Human trials have ranged 0.3-2.0 mg; never self-dose. Overdose carries thrombosis risk.

What if I have kidney disease?

EPO regulation depends on renal function; kidney disease patients have altered EPO metabolism. Only use under medical supervision.

References & further reading

EPO receptor biology and tissue protection: Cardiovascular Research and Journal of Pharmacology and Experimental Therapeutics
ARA-290 clinical trials in neuropathy: limited published literature; phase 2 results in specialized endocrinology journals
Thrombosis and EPO agonist risk: hematology and nephrology literature
JAK2-STAT5 signaling: molecular biology and cell signaling texts
WADA banned substances list: official WADA documentation